Werewolf Therapeutics (NASDAQ:HOWL) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Werewolf Therapeutics (NASDAQ:HOWL) posted its quarterly earnings results on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.03), Zacks reports. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.

Werewolf Therapeutics Trading Down 0.4 %

NASDAQ HOWL opened at $1.23 on Tuesday. Werewolf Therapeutics has a twelve month low of $1.03 and a twelve month high of $6.89. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. The stock has a market cap of $54.59 million, a price-to-earnings ratio of -0.80 and a beta of 0.37. The firm’s 50 day moving average price is $1.38 and its two-hundred day moving average price is $1.83.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a report on Tuesday, November 19th. JMP Securities lowered their price objective on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research report on Tuesday, January 14th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.